Wuhan iRegene Therapeutics Co., Ltd. announced that it has received $15,700,000 in funding led by Changjiang Securities Company Limited on January 24, 2022. The transaction included participation from other investors.
Changjiang Securities Company Limited
Equities
000783
CNE000000SH3
Investment Banking & Brokerage Services
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.32 CNY | -0.19% | -1.66% | -1.12% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.12% | 4.07B | |
-12.04% | 27.12B | |
-10.28% | 15.13B | |
-6.30% | 13.12B | |
+41.38% | 12.39B | |
-21.46% | 11.32B | |
-8.05% | 8.61B | |
-20.18% | 6.42B | |
-8.46% | 5.48B | |
-4.41% | 5.31B |
- Stock Market
- Equities
- 000783 Stock
- News Changjiang Securities Company Limited
- Wuhan iRegene Therapeutics Co., Ltd. announced that it has received $15.700000 million in funding from Changjiang Securities Company Limited and other investors.